Rajamani Ramkumar, Wu Sophie, Rodrigo Iyoncy, Gao Mian, Low Simon, Megson Lisa, Wensel David, Pieschl Rick L, Post-Munson Debra J, Watson John, Langley David R, Ahlijanian Michael K, Bristow Linda J, Herrington James
Molecular Discovery Technologies, Wallingford, Connecticut, Princeton, New Jersey, and Waltham, Massachusetts (R.R., S.W., I.R., M.G., S.L., L.M., D.W., D.R.L.); Discovery Biology (R.L.P., D.J.P.-M., M.K.A., L.J.B., J.H.) and Lead Discovery and Optimization (J.W.), Bristol-Myers Squibb Company, Wallingford, Connecticut
Molecular Discovery Technologies, Wallingford, Connecticut, Princeton, New Jersey, and Waltham, Massachusetts (R.R., S.W., I.R., M.G., S.L., L.M., D.W., D.R.L.); Discovery Biology (R.L.P., D.J.P.-M., M.K.A., L.J.B., J.H.) and Lead Discovery and Optimization (J.W.), Bristol-Myers Squibb Company, Wallingford, Connecticut.
Mol Pharmacol. 2017 Sep;92(3):310-317. doi: 10.1124/mol.117.108712. Epub 2017 Jun 23.
The Na1.7 voltage-gated sodium channel is implicated in human pain perception by genetics. Rare gain of function mutations in Na1.7 lead to spontaneous pain in humans whereas loss of function mutations results in congenital insensitivity to pain. Hence, agents that specifically modulate the function of Na1.7 have the potential to yield novel therapeutics to treat pain. The complexity of the channel and the challenges to generate recombinant cell lines with high Na1.7 expression have led to a surrogate target strategy approach employing chimeras with the bacterial channel NaAb. In this report we describe the design, synthesis, purification, and characterization of a chimera containing part of the voltage sensor domain 2 (VSD2) of Na1.7. Importantly, this chimera, DII S1-S4, forms functional sodium channels and is potently inhibited by the Na1.7 VSD2 targeted peptide toxin ProTx-II. Further, we show by [I]ProTx-II binding and surface plasmon resonance that the purified DII S1-S4 protein retains high affinity ProTx-II binding in detergent. We employed the purified DII S1-S4 protein to create a scintillation proximity assay suitable for high-throughput screening. The creation of a Na1.7-NaAb chimera with the VSD2 toxin binding site provides an important tool for the identification of novel Na1.7 inhibitors and for structural studies to understand the toxin-channel interaction.
Na1.7电压门控钠通道在遗传学上与人的疼痛感知有关。Na1.7中罕见的功能获得性突变会导致人类自发疼痛,而功能丧失性突变则会导致先天性无痛觉。因此,特异性调节Na1.7功能的药物有潜力产生治疗疼痛的新型疗法。该通道的复杂性以及生成高表达Na1.7的重组细胞系所面临的挑战,导致了一种采用与细菌通道NaAb嵌合体的替代靶点策略。在本报告中,我们描述了一种包含Na1.7电压传感器结构域2(VSD2)部分的嵌合体的设计、合成、纯化和表征。重要的是,这种嵌合体DII S1-S4形成了功能性钠通道,并被靶向Na1.7 VSD2的肽毒素ProTx-II有效抑制。此外,我们通过[I]ProTx-II结合和表面等离子体共振表明,纯化的DII S1-S4蛋白在去污剂中保留了对ProTx-II的高亲和力结合。我们使用纯化的DII S1-S4蛋白创建了一种适用于高通量筛选的闪烁邻近分析。具有VSD2毒素结合位点的Na1.7-NaAb嵌合体的创建为鉴定新型Na1.7抑制剂和进行结构研究以了解毒素-通道相互作用提供了重要工具。